Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 558-566

  Kang, Kyungsu ^a   Nho, Chu Won ^a   Kim, Nam Doo ^b   Song, Dae Geun ^a   Park, Young Gyun ^a   Kim, Minkyun ^d   Pan, Cheol Ho ^a   Shin, Dongyun ^c   Oh, Seung Hyun ^c   Oh, Ho Suk ^e  

^a Korea Institute of Science and Technology   (South Korea)

^b Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

^c Gachon University   (South Korea)

^d Seoul National University   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

ATP binding pocket; Daurinol; Ovarian cancer; Secondary leukemia; Topoisomerase II inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLIN A; CYCLIN E; DAURINOL; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ETOPOSIDE; GYRASE INHIBITOR; LIGNAN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; NAPHTHALENE DERIVATIVE; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATPASE ACTIVITY ASSAY; BINDING SITE; BIOCHEMISTRY; CANCER CELL LINE; CANCER INHIBITION; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; MALE; MOLECULAR DOCKING; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; S PHASE CELL CYCLE CHECKPOINT; SIMULATION; TESTIS CANCER; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; CELL PROLIFERATION; DRUG EFFECTS; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZODIOXOLES; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; MOLECULAR DOCKING SIMULATION; NAPHTHALENES; OVARIAN NEOPLASMS; S PHASE; TOPOISOMERASE II INHIBITORS;

EID: 84902583141     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2442     Document Type: Article

References (25)

1. Bailly C: Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Chem Rev 112: 3611-3640, 2012.
2. Pogorelcnik B, Perdih A and Solmajer T: Recent advances in the development of catalytic inhibitors of human DNA topo-isomerase IIα as novel anticancer agents. Curr Med Chem 20: 694-709, 2013.
3. Ezoe S: Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9: 2444-2453, 2012.
4. Chen W, Qiu J and Shen YM: Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. Drug Discov Ther 6: 230-237, 2012.
5. Kang K, Oh SH, Yun JH, et al: A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide. Neoplasia 13: 1043-1057, 2011.
6. Batsuren D, Batirov EK, Malikov VM, Zemlyanskii VN and Yagudaev MR: Arylnaphthalene lignans of Haplophyllum dauricum. The structure of daurinol. Chem Nat Compd 17: 223-225, 1981.
7. Graham JG, Quinn ML, Fabricant DS and Farnsworth NR: Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol 73: 347-377, 2000.
8. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521, 1998.
9. Park JE, Lee J, Seo SY and Shin D: Regioselective route for arylnaphthalene lactones: convenient synthesis of taiwanin C, justicidin E, and daurinol. Tetrahedron Lett 55: 818-820, 2014.
10. Lanzetta PA, Alvarez LJ, Reinach PS and Candia OA: An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 100: 95-97, 1979. (Pubitemid 10157636)
11. Kang K, Jin YM, Jeon H, et al: The three proline residues (P25, P242, and P434) of Agrobacterium CP4 5-enolpyruvylshikimate-3-phosphate synthase are crucial for the enzyme activity. Plant Biotechnol Rep 4: 329-334, 2010.
12. Jun KY, Lee EY, Jung MJ, et al: Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy- 1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Eur J Med Chem 46: 1964-1971, 2011.
13. Robinson MJ, Corbett AH and Osheroff N: Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 32: 3638-3643, 1993. (Pubitemid 23126939)
14. Kang K, Lee HJ, Kim CY, et al: The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme. Biol Pharm Bull 30: 2352-2359, 2007. (Pubitemid 350223741)
15. Kang K, Lee HJ, Yoo JH, et al: Cell and nuclear enlargement of SW480 cells induced by a plant lignan, arctigenin: evaluation of cellular DNA content using fluorescence microscopy and flow cytometry. DNA Cell Biol 30: 623-629, 2011.
16. Kang K, Lee SB, Yoo JH and Nho CW: Flow cytometric fluorescence pulse width analysis of etoposide-induced nuclear enlargement in HCT116 cells. Biotechnol Lett 32: 1045-1052, 2010.
17. Roca J: The mechanisms of DNA topoisomerases. Trends Biochem Sci 20: 156-160, 1995.
18. Larsen AK, Escargueil AE and Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99: 167-181, 2003. (Pubitemid 36897748)
19. Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91: 223-231, 2004.
20. Masai H, Matsumoto S, You Z, Yoshizawa-Sugata N and Oda M: Eukaryotic chromosome DNA replication: where, when, and how? Annu Rev Biochem 79: 89-130, 2010.
21. DeGregori J, Kowalik T and Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 15: 4215-4224, 1995.
22. Gui M, Shi DK, Huang M, et al: D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα. Invest New Drugs 29: 800-810, 2011.
23. Schmeisser S, Schmeisser K, Weimer S, et al: Mitochondrial hormesis links low-dose arsenite exposure to lifespan extension. Aging cell 12: 508-517, 2013.
24. Dengg M and van Meel JC: Caenorhabditis elegans as model system for rapid toxicity assessment of pharmaceutical compounds. J Pharmacol Toxicol Methods 50: 209-214, 2004. (Pubitemid 39440718)
25. van den Heuvel S and Kipreos ET: C. elegans cell cycle analysis. Methods Cell Biol 107: 265-294, 2012.